Autoimmune Disease Diagnostics Market Analysis

Autoimmune Disease Diagnostics Market Analysis

The systemic autoimmune disease segment accounted for substantial market share in 2021 and is expected to register over 7% CAGR during the estimation timeframe. This notable market share is pertaining to rapid increase of systemic autoimmune diseases associated with increasing number of morbidity and mortality. Some of the major diseases that result in systemic autoimmune disease include rheumatoid arthritis, systemic lupus erythematosus (SLE), psoriasis, multiple sclerosis, etc. Among patients suffering from rheumatoid arthritis, the immune systems of these patients attack the synovial tissues in joints leading to redness, warmth, soreness, and stiffness in the joints.
 

According to the reports of the National Center of Biotechnology Information (NCBI), in the U.S. and other western nations of northern Europe, the annual incidence of rheumatoid arthritis is around 40 per 100,000 people. Additionally, over 1.5 million people in U.S. are suffering from rheumatoid arthritis and are likely to grow in the near future.
 

Therefore, the increasing prevalence of these systemic autoimmune disease and treatments associated with them via advanced automation technology will fuel the market demand. Further, the ongoing clinical studies & R&D efforts to assess and promote efficacy is set to proliferate the autoimmune disease diagnostics market size.
 

Based on test type, the autoimmune disease diagnostics market is segmented into antinuclear antibody tests, autoantibody tests, c-reactive protein (CRP), complete blood count (CBC), urinalysis and others. The antinuclear antibody tests segment was valued at over USD 479 million in 2021 and is anticipated to grow at a 6.8% CAGR from 2022-2030. This dominant market growth is majorly attributed to the high prevalence of chronic ailments and diseases that attack immune systems such as type 1 diabetes, myasthenia gravis, Addison’s disease, rheumatoid arthritis, etc.
 

Antinuclear antibody tests detect antinuclear antibodies in the blood. Myasthenia gravis is a genetically susceptible autoimmune disease. According to NCBI, in 2021, the prevalence rate of myasthenia gravis in the U.S. was around 20 individuals per 100,000 population and it is increasing at a steady pace. Thus, the high prevalence of genetical autoimmune diseases is expected to expedite the autoimmune disease diagnostics industry landscape in the coming years.
 

The hospitals segment accounted for a majority market share of more than 53% in 2021 and is expected to proliferate the market growth during the analysis period. This significant market share is owing to the surged adoption of autoimmune disease diagnostic procedures in hospitals associated to complex interventional surgeries. Hospitals consists of sophisticated technology labs, provide effective physiotherapy sessions, improved patient aid and counselling, and other services that ensure market expansion and create demand for these facilities.
 

Furthermore, the rise in the incidence of several chronic diseases, and neurological diseases that can result in autoimmune diseases will drive the market expansion. Increasing availability of highly skilled medical and healthcare professionals, as well as advanced facilities, are some of the key factors that contribute to segmental progression thereby leading to overall market growth.
 

The U.S. autoimmune disease diagnostics market is projected to reach more than USD 660 million by 2030. This dominant market share is owing to several factors such as the rising autoimmune disease burden, increasing healthcare expenditure, product launches, and presence of major players across the country. According to the National Stem Cell Foundation, approximately between 5% to 8% of the total U.S. population suffers from multiple autoimmune disorders accounting for around 1 in 15 people undergoing autoimmune disease diagnostics treatment.
 

Additionally, as per the reports of the National Institute of Environmental Health Sciences, in 2021, around 24 million people in the U.S. were affected with autoimmune diseases and additional 8 million people were having autoantibodies, blood molecules that might create chances to develop autoimmune disease. Further, the increasing awareness and favorable government initiatives will help to witness a lucrative market growth. Technologically advanced diagnostic centers and adoption of automation technology in diagnosis and treatment will provide ample growth opportunities. Also, the presence of major players in the country and launch of novel products is expected to fuel the regional market statistics.